The document is a financial analysis report by Morgan Stanley on Biogen Idec Inc., covering stock ratings, financial performance, and future projections. It includes detailed tables on revenue, income statements, balance sheets, and cash flow statements. The report highlights Biogen's strong product growth, particularly Tecfidera, and provides a risk-reward analysis with price targets.
documents/EFTA00598607.pdf
{}